UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported):
January
28, 2008
IMMUNOSYN
CORPORATION
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
|
005-82677
|
|
20-5322896
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
4225
Executive Square, Suite 260
La
Jolla, California
|
|
92037
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code:
888-853-3663
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
|
|
|
x
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Investor
Presentation
Below
is
a copy of the transcript of the interview given by Stephen Ferrone, President
and CEO of Immunosyn, published on January 25, 2008 in the CEOCFO newsletter.
Immunosyn’s
SF-1019 Technology
Has
Demonstrated That It May Up-Regulate
The
Innate Immune System, Modulates The Adaptive Immune System And Has Demonstrated
No Toxic Effects In Animal Trials And Pre-Clinical Human
Studies
Healthcare
Biotechnology
(IMYN-OTC:
BB)
Immunosyn
Corporation
4225
Executive Square, Suite 260
La
Jolla,
CA 92037
Stephen
D. Ferrone
President
and CEO
BIO:
Stephen
D. Ferrone
CEO,
President and Board Member
Mr.
Ferrone is a veteran marketing and sales executive with demonstrated national
leadership of strategic and tactical distribution initiatives through
intermediary channels. He has a proven career of growing and managing businesses
including nine years of service with ABN AMRO Asset Management as genesis
architect of its marketing strategy and responsibility for its mutual fund
and
separate accounts distribution network. Mr. Ferrone is a graduate of
Northwestern University and Loyola School of Law and began his professional
career in Chicago, Illinois as a felony trial prosecutor for Cook County. He
later transitioned into the field of comprehensive wealth management as a
principal in a successful fee-based money management practice, a concept that
was still new at that time. He sold his interest in that business to become
Regional Marketing Director at Schwab Institutional where he opened the Midwest
office. He built and led a team providing technology solutions to asset
managers, achieving a 76% per year increase in sales with consistent top ranked
profitability. Subsequently, as the National Sales Director for ABN AMRO, Mr.
Ferrone set the strategic marketing plan and led the sales team he created
to
raise net new investment sales of over $9 billion dollars over his nine-year
tenure.
Company
Profile:
La
Jolla,
CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and
distribute life-enhancing therapeutics. Currently, the company has exclusive
worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC,
to
market, sell and distribute SF-1019, a compound that was developed from
extensive research into Biological Response Modifiers (BRMs). Argyll
Biotechnologies, LLC has initiated the process for regulatory approval of
SF-1019 in several countries and preparations for clinical trials are underway
in both the US and Europe. Research suggests that SF-1019 has the potential
to
affect a number of clinical conditions including complications from Diabetic
Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune
disorders such as Multiple Sclerosis (MS) and neurological disorders such as
Chronic Inflammatory Demyelinating Polyneuropathy
(CIDP)
and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).
Interview
conducted by:
Lynn
Fosse, Senior Editor
CEOCFOinterviews.com
CEOCFO:
Mr. Ferrone, you are new as CEO at Immunosyn; what attracted you, and what
is
the vision?
Mr.
Ferrone: “What attracted me was the science; there are so many unmet needs in
the world with respect to treating diseases and the science behind SF-1019
was
tremendously compelling. As a biological response modifier, SF-1019 interacts
with the autoimmune system. Autoimmune related diseases account for about half
of the diseases on the planet. If there is a potentially effective treatment
for
this area of disease, it offers great opportunity.”
CEOCFO:
Would you tell us more about SF-1019?
Mr.
Ferrone: “The scientists involved believe, and it is our opinion, that SF-1019
is a scientific breakthrough. The reason for this is that SF-1019 upregulates
the innate immune system and modulates the adaptive immune system. This is
particularly unique. Many biological response modifiers will do one or the
other
but not both and unfortunately most have toxic effects, whereas SF-1019 has
demonstrated in animal trials and pre-clinical human studies not to have those
toxic effects.”
CEOCFO:
Are you doing this in partnership?
Mr.
Ferrone: “Yes. Immunosyn, the public company, is a developmental distribution
company awaiting the approval of the biopharmaceutical SF-1019. Argyll
Biotechnologies, LLC, Immunosyn’s strategic partner and largest shareholder, is
the company who has brought this biopharmaceutical through its ten-year period
of development to the point where it is a fully-developed drug.” It is now
Argyll Biotechnologies’ responsibility to move SF-1019 through the clinical
trials and through the various jurisdictional approval processes.”
CEOCFO:
Where are you in the process of getting it to people?
Mr.
Ferrone: “Regulatory approval processes for SF-1019 have been initiated by
Argyll Biotechnologies, LLC in several countries. Additionally, in both the
US
and Europe preparations for clinical trials are underway. Research indicates
that SF-1019 has the potential to affect neurological disorders such as Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic
Dystrophy Syndrome (RSD or RSDS), autoimmune disorders such as Multiple
Sclerosis (MS), and a number of clinical conditions including complications
from
Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers
(DU).”
CEOCFO:
Is it a lot easier in Europe?
Mr.
Ferrone: “It is a process wherever you go. Certainly, the EMEA in the European
Union has their protocol just as the FDA does here. The standards are equally
rigorous and stringent as to safety & efficacy in both the US and the EU. So
really, the question is not whether it is easier or harder; but one of choosing
the most efficient and timely strategy for each given
jurisdiction.”
CEOCFO:
What is the financial picture of the company?
Mr.
Ferrone: “Under the terms of our exclusive license agreement, Argyll
Biotechnologies is responsible for all regulatory approvals and clinical trials
including those required by the EMEA and FDA together with their associated
costs. However, we are working on the capitalization of Immunosyn now. We hope
to be able to make an announcement about that soon.”
CEOCFO:
What is the plan going forward?
Mr.
Ferrone: “Our job is to raise awareness in the patient, medical and investor
communities as to the potential of SF-1019. We will be setting up distribution
protocols for anticipated approvals as they come from their respective
jurisdictions. It is also our responsibility to communicate with Argyll
Biotechnologies, to monitor their progress and to update our stakeholders as
milestone accomplishments occur along the way.”
CEOCFO:
There are many new ideas that are fighting for attention; how do you get the
various components that you need for the public and investors to pay
attention?
Mr.
Ferrone: “It is top down, bottom up; attending conferences, speaking engagements
and reaching out to intermediaries and individual investors who might be
interested in Immunosyn. In addition, we are proactively creating a face and
increasing visibility in the market place. Those reading this article who would
like more information can contact us through our website.”
CEOCFO:
Are you planning to add other technologies and products?
Mr.
Ferrone: “Yes. Certainly, our immediate focus is on preparing for the
achievement of successful clinical trials and the approval to distribute SF-1019
worldwide, as is our right through our exclusive license agreement with Argyll
Biotechnologies. SF-1019 is the platform technology that may point the way
for
the future development and refinement of many promising innovative and
cutting-edge therapeutics. However, as we develop a revenue stream it will
also
allow for future acquisitions.”
CEOCFO:
You are looking at prescription veterinary treatments, why is that an area
of
interest?
Mr.
Ferrone: “There are certain autoimmune related indications from which animals
suffer. Our Scientific Advisory Board believes that there are potential
applications for iterations of SF-1019 to be developed for use in the veterinary
arena.”
CEOCFO:
Are you looking at marketing and distribution?
Mr.
Ferrone: “That is the second step. We are at the awareness stage, creating a
foundation and developing awareness for Immunoysn and SF-1019 now. On an
operational basis, as milestones with SF- 1019 are achieved and we get closer
to
distribution, then marketing and distribution plans for SF-1019 will become
our
primary focus.”
CEOCFO:
Why should potential investors pick you out of the crowd?
Mr.
Ferrone: “I read in a magazine recently an article about a very well-known drug
company and it included a comment about the industry at large. Many of the
major
drug companies are seeing their patents and their exclusive distribution rights
running out. This is with respect to some of the key medications that they
have
been selling for a long period of time. Secondly, the whole perception of how
to
create drugs is shifting from what it has been over the last hundred years,
which was lab driven, to something that is more biologically friendly. The
role
of Immunosyn really is to seek biopharmaceutical solutions that work with the
body, not against it. It is our vision to market & distribute treatments
that are non-toxic in consequence and that will help the body do what it does
naturally, only better. The potential here is to relieve pain and suffering
throughout the world, as well as create revenue streams. Companies such as
Immunosyn that are striving to market biologically friendly, cutting edge
biopharmaceutical products such as SF-1019 are going to get visibility.”
CEOCFO:
What should people take away from reading this interview? Mr. Ferrone: “We have
a drug that is fully developed, which our Scientific Advisory Board believes
has
demonstrated safety and efficacy for indications for which we hope the treatment
will be approved. We are in the marketplace raising awareness and are cognizant
of the need to set up a viable distribution system. With respect to SF-1019,
we
are at the cutting-edge of where drug development and therapies are today.
The
two Orphan Diseases for which Argyll Biotechnologies plans to seek FDA approval
in the US are Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and
Reflex Sympathetic Dystrophy (RSD or RSDS). However, the overall target market
is potentially broader. It could include indications such as Multiple Sclerosis
(MS), from which an estimated 2.5 million people suffer worldwide. There is
also
the potential for SF-1019 to be used in treating complications from Diabetic
Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU). Worldwide,
approximately 246 million people have Diabetes Mellitus, of those, 1 in 6 will
develop a foot ulcer and an estimated 50% have a Diabetic Neuropathy (DN).
Therefore, there is certainly a large potential market for SF-1019. From a
business standpoint as well as a humanitarian standpoint, we feel there is
great
potential.”
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
IMMUNOSYN
CORPORATION
|
|
|
|
|
|
|
Date: January
28, 2008
|
By:
|
/s/
Stephen
D. Ferrone,
|
|
|
|
Stephen
D. Ferrone,
|
|
|
|
President
|
|